Overview

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
0
Participant gender:
Male
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with bone marrow transplantation is a more effective treatment for men with germ cell tumors. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with bone marrow transplantation in treating men with relapsed germ cell tumors.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UNICANCER
Treatments:
Carboplatin
Cyclophosphamide
Etoposide
Ifosfamide
Vinblastine
Criteria
DISEASE CHARACTERISTICS: Diagnosis of testicular or extragonadal male germ cell tumors Must
meet 1 of the following conditions after completion of platinum-based first-line
chemotherapy: Complete remission (CR) followed by relapse Partial remission (PR) Prior
resection of viable malignancy with elevated tumor markers allowed Initial bulky disease
with no CR (significantly reduced but still abnormal in plateau) allowed if there is an
increase in biological tumor markers or development of new metastases Seminoma with relapse
after CR or PR to cisplatin-based chemotherapy allowed No pure seminoma pre-treated with
carboplatin No refractory disease (i.e., documented increase in tumor burden and/or serum
tumor marker level during or within 1 month after platinum-containing chemotherapy) CNS
involvement allowed

PATIENT CHARACTERISTICS: Age: 16 and over Sex: Male Performance status: WHO 0-2 OR
Karnofsky 50-100% Life expectancy: No limits on life expectancy due to severe non-malignant
disease Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
Cardiovascular: No severe cardiac disease that would interfere with study therapy
Pulmonary: No severe pulmonary disease that would interfere with study therapy Other: HIV
negative No severe neurologic or metabolic disease that would interfere with study therapy
No psychological, socioeconomic, or geographic circumstances that would preclude study No
other concurrent malignancy

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy for
metastatic disease allowed Surgery: See Disease Characteristics Prior surgery for
metastatic disease allowed